Syngene International Limited shareholders approved a final dividend of ₹1.25 per equity share for FY26 and ratified key board composition changes during its 33rd Annual General Meeting (AGM) held on July 29, 2026. While promoter entities backed all resolutions unanimously, public institutional investors demonstrated significant dissent against the appointment of Dr. Arun Chandavarkar as an Independent Director, highlighting divergent views on governance leadership. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM), saw an 87.32% turnout from the 403,669,147 shares held on the record date of July 22, 2026. All nine resolutions passed with the requisite majority under Section 108 of the Companies Act, 2013, scrutinized by V. Sreedharan and Associates.

The AGM commenced at 3:31 pm (IST) with 117 members present, including one promoter representative and 116 public shareholders. Remote e-voting was open from July 24 to July 28, 2026, with votes unblocked on July 29 at 4:35 pm. A total of 352,496,949 shares were polled across nine resolutions. The promoter group, holding 212,283,697 shares, voted in favor of all items. Public non-institutional investors also showed strong support, with approval rates exceeding 97% for most items. However, public institutional investors, holding 159,480,553 shares, selectively opposed specific governance appointments.

Voting Results by Resolution

The voting pattern reveals clear alignment between promoters and non-institutional public shareholders, contrasted by institutional skepticism on certain board appointments. Institutional support varied significantly, ranging from 100% for financial statements to just 40.28% for Dr. Chandavarkar’s appointment.

Governance and Leadership Changes

The Board appointed M/S S.R. Batliboi & Associates LLP as Statutory Auditors, succeeding B S R & Co. LLP. Mr. Ankit Mittal, Partner at S.R. Batliboi, attended the meeting. The Board composition was updated with the appointment of Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors. Professor Catherine Rosenberg was reappointed after retiring by rotation. Ms. Vinita Bali was recommended for appointment as a Non-Executive Director. The remuneration for Mr. Siddharth Mittal as Managing Director and CEO was also approved.

Analytical Observation

The voting pattern reveals a sharp divergence between promoter and institutional interests regarding governance appointments. While promoters backed all measures unanimously, institutional investors voted against 59.72% of the shares polled for Dr. Arun Chandavarkar’s appointment (Resolution 8), resulting in only 76.25% overall support. Similarly, the resolution approving director remuneration in case of inadequate profits (Resolution 5) received only 74.84% support from institutions, indicating heightened scrutiny on executive compensation structures. This suggests that while financial outcomes like dividends remain uncontested, institutional stakeholders are actively leveraging voting rights to influence board composition and remuneration policies.

Syngene International management has issued updated guidance for FY27, projecting a single-digit decline in revenue in rupee terms alongside EBITDA margins in the mid-20s for the full financial year. The revised outlook reflects the absence of offtake from Zoetis and attrition of some Research Services clients, with significant impact anticipated in H1 FY27, according to a concall update.

FY27 Financial Guidance

Management has outlined key financial expectations for FY27, incorporating the impact of recent business developments. The guidance reflects a cautious near-term outlook, particularly in the first half of the fiscal year, while anticipating recovery in the second half.

Key Drivers of Revised Guidance

The revised guidance is primarily driven by the absence of offtake from Zoetis and the attrition of some Research Services clients, both of which are expected to weigh significantly on performance in H1 FY27. Additionally, the Bayview facility will not be capitalised during FY27, resulting in minimal associated expenses reflected in the profit and loss statement for this fiscal year.

Margin Improvement Levers

Despite the near-term revenue pressure, management expects margin improvement to materialise in H2 FY27. This recovery is anticipated to be supported by revenue uptake in the second half of the fiscal year, along with ongoing cost optimisation programmes covering employee-related costs and other operational expenses.

Outlook Beyond FY27

Looking ahead, Syngene International anticipates a return to profitable and sustainable growth from FY28 onwards. This recovery is expected to be driven by commercial momentum, improved asset utilisation, and enhanced operational efficiency, as highlighted in the concall update.